Medicenna Therapeutics Company Description
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases.
It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma.
The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKITTM for cancer; and MDNA132, an IL-13 Superkine for various tumors.
Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Fahar Merchant |
Contact Details
Address: 2 Bloor Street West Toronto, Alberta M4W 3E2 Canada | |
| Phone | 416 648 5555 |
| Website | medicenna.com |
Stock Details
| Ticker Symbol | MDNAF |
| Exchange | OTCMKTS |
| Fiscal Year | April - March |
| Reporting Currency | CAD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Fahar Merchant Ph.D. | Founder, Chairman, President and Chief Executive Officer |
| Rosemina Merchant B.Sc., M.E.Sc | Founder and Chief Development Officer |
| David Hyman CA, CBV | Chief Financial Officer |
| Dr. Samuel R. Denmeade M.D. | Scientific Advisor |